Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer.
By E. Woo, Christina S. Chu, Theresa J. Goletz, Katia Schlienger, H. Yeh, George Coukos, Stephen C. Rubin, Larry R. Kaiser, Carl H. June. Cancer Research, 2001
1,198 citations recorded by the source corpus.
View Paper: https://www.semanticscholar.org/paper/94e90dd349c2c075e388196c5cdc10fdbefb9685
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
- Marc Beyer
- Joachim L. Schultze
- Lars A. Ormandy
- Helen Y Wang
- C. Zappa
- Guangyong Peng
- A. Wolf
- Dean Anthony Lee
Citations in the corpus
- Prevalence of Regulatory T Cells Is Increased in Peripheral Blood and Tumor Microenvironment of Patients with Pancreas or Breast Adenocarcinoma1 (2002, unknown): “A previous study demonstrated that large numbers of CD4 25 lymphocytes infiltrate the tumor microenvironment of non-small cell lung cancers and ovarian cancers (13).”
- The tumor microenvironment and its role in promoting tumor growth (2008, background): “Given the expansion of these populations in the circulation and tumor tissues of cancer patients (Woo et al., 2001; Liyanage et al., 2002; Curiel et al., 2004; Shevach, 2004; Strauss et al., 2007b), it is important to perform Treg phenotypic and functional evaluations to be able to define their role”
- T Regulatory Cells: Key Players in Tumor Immune Escape and Angiogenesis (2012, background): “Woo and colleagues (4) were the first to report an increased”
- Increase of regulatory T cells in the peripheral blood of cancer patients. (2003, background): “For humans, only few data are available to date (17).”
- Regulatory T cells in cancer. (2006, background): “were the first to report increased percentages of CD4CD25 Treg cells in TIL in non-small cell lung cancer and ovarian cancer.(66) These Treg cells were shown to secret TGFβ providing first evidence that Treg cells contribute to immune dysfunction in cancer patients.”
- Non-small cell lung cancer: current treatment and future advances. (2016, background): “The goal of vaccine therapy in NSCLC is to shift the immune balance in favor of activation so that the host may launch a response to tumor-associated antigens (87,88).”